A Two-sided Loop X-Ray Solar Coronal Jet Driven by a Minifilament Eruption

Most of the commonly discussed solar coronal jets are the type that consist of a single spire extending approximately vertically from near the solar surface into the corona. Recent research supports that eruption of a miniature filament (minifilament) drives many such single-spire jets and concurrently generates a miniflare at the eruption site. A different type of coronal jet, identified in X-ray images during the Yohkoh era, are two-sided loop jets, which extend from a central excitation location in opposite directions, along low-lying coronal loops that are more-or-less horizontal to the surface. We observe such a two-sided loop jet from the edge of active region (AR) 12473, using data from Hinode X-Ray Telescope (XRT) and Extreme Ultraviolet Imaging Spectrometer (EIS), and from Solar Dynamics Observatory's (SDO) Atmospheric Imaging Assembly (AIA) and Helioseismic and Magnetic Imager (HMI). Similar to single-spire jets, this two-sided loop jet results from eruption of a minifilament, which accelerates to over 140 km s−1 before abruptly stopping after striking an overlying nearly horizontal-loop field at ~30,000 km in altitude and producing the two-sided loop jet. An analysis of EIS raster scans shows that a hot brightening, consistent with a small flare, develops in the aftermath of the eruption, and that Doppler motions (~40 km s−1) occur near the jet formation region. As with many single-spire jets, the magnetic trigger here is apparently flux cancelation, which occurs at a rate of ~4 × 1018 Mx hr−1, broadly similar to the rates observed in some single-spire quiet-Sun and AR jets. An apparent increase in the (line-of-sight) flux occurs within minutes of the onset of the minifilament eruption, consistent with the apparent increase being due to a rapid reconfiguration of low-lying fields during and soon after the minifilament-eruption onset

Further Evidence for the Minifilament-eruption Scenario for Solar Polar Coronal Jets

Abstract We examine a sampling of 23 polar-coronal-hole jets. We first identified the jets in soft X-ray (SXR) images from the X-ray telescope (XRT) on the Hinode spacecraft, over 2014–2016. During this period, frequently the polar holes were small or largely obscured by foreground coronal haze, often making jets difficult to see. We selected 23 jets among those adequately visible during this period, and examined them further using Solar Dynamics Observatory’s (SDO) Atmospheric Imaging Assembly (AIA) 171, 193, 211, and 304 Å images. In SXRs, we track the lateral drift of the jet spire relative to the jet base’s jet bright point (JBP). In 22 of 23 jets, the spire either moves away from (18 cases) or is stationary relative to (4 cases) the JBP. The one exception where the spire moved toward the JBP may be a consequence of line-of-sight projection effects at the limb. From the AIA images, we clearly identify an erupting minifilament in 20 of the 23 jets, while the remainder are consistent with such an eruption having taken place. We also confirm that some jets can trigger the onset of nearby “sympathetic” jets, likely because eruption of the minifilament field of the first jet removes magnetic constraints on the base-field region of the second jet. The propensity for spire drift away from the JBP, the identification of the erupting minifilament in the majority of jets, and the magnetic-field topological changes that lead to sympathetic jets, all support or are consistent with the minifilament-eruption model for jets.</jats:p

Small-scale EUV features as the drivers of coronal upflows in the quiet Sun

Context. Coronal upflows in the quiet Sun are seen in a wide range of features, including jets and filament eruptions. The in situ measurements from Parker Solar Probe within ≈0.2 au have demonstrated that the solar wind is highly structured, showing abrupt and near-ubiquitous magnetic field reversals (i.e., switchbacks) on different timescales. The source of these structures has been associated with supergranular structures on the solar disc. This raises the question of whether there are additional small coronal features that contribute energy to the corona and produce plasma that potentially feeds into the solar wind. / Aims. During the Solar Orbiter first science perihelion, high-resolution images of the solar corona were recorded using the Extreme Ultraviolet High Resolution Imager (HRIEUV) from the Extreme Ultraviolet Imager (EUI). The Hinode spacecraft was also observing at the same location providing coronal spectroscopic measurements. Combining the two datasets allows us to determine the cause of the weak upflows observed in the quiet Sun and the associated activity. / Methods. We used a multi-spacecraft approach to characterise regions of upflows. The upflows were identified in the Fe XII emission line by the Hinode EUV Imaging Spectrometer (EIS). We then used imaging data from the Atmospheric Imaging Assembly on board the Solar Dynamics Observatory (SDO/AIA) and the High Resolution Imagers (HRI) from EUI on board the Solar Orbiter to identify coronal features and magnetic field data from the SDO Helioseismic and Magnetic Imager (HMI). Interface Region Imaging Spectrograph (IRIS) observations were also used to understand the photospheric and chromospheric driving mechanisms. / Results. We have identified two regions of coronal upflows in the quiet Sun, with respective sizes and lifetimes of (20 Mm2, 20 min) and (180 Mm2, several hours), which are contrasting dynamic events. Both examples show weak flux cancellation, indicating that the source of the upflows and enhancements is related to the magnetic field changes. The first event, a larger upflow region, shows velocities of up to −8.6 km s−1 at the footpoint of a complex loop structure. We observe several distinct extreme ultraviolet (EUV) features including frequent loop brightenings and plasma blobs travelling along closed coronal loops. The second upflow region has velocities of up to −7.2 km s−1. Within it, a complex EUV feature that lasts for about 20 min can be seen. This main feature has several substructures. During its appearance, a clear mini-filament eruption takes place at its location, before the EUV feature disappears. / Conclusions. Two features, with contrasting properties, show upflows with comparable magnitudes. The first event, a complex loop structure, shares several similarities with active region upflows. The second one, a complex small-scale feature that could not have been well resolved with previous instruments, triggered a cascade of events, including a mini-filament that lead to a measurable upflow. This is remarkable for an EUV feature that many instruments can barely resolve. The complexity of the two events, including small loop brightenings and travelling plasma blobs for the first and EUV small-scale loops and mini-filament for the second one would not have been identifiable as the sources of upflow without an instrument with the spatial resolution of HRIEUV at this distance to the Sun. These results reinforce the importance of the smallest-scale features in the Sun and their potential relevance for and impact on the solar corona and the solar wind

Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies

BACKGROUND: Health care for people living with HIV has improved substantially in the past two decades. Robust estimates of how these improvements have affected prognosis and life expectancy are of utmost importance to patients, clinicians, and health-care planners. We examined changes in 3 year survival and life expectancy of patients starting combination antiretroviral therapy (ART) between 1996 and 2013. METHODS: We analysed data from 18 European and North American HIV-1 cohorts. Patients (aged ≥16 years) were eligible for this analysis if they had started ART with three or more drugs between 1996 and 2010 and had at least 3 years of potential follow-up. We estimated adjusted (for age, sex, AIDS, risk group, CD4 cell count, and HIV-1 RNA at start of ART) all-cause and cause-specific mortality hazard ratios (HRs) for the first year after ART initiation and the second and third years after ART initiation in four calendar periods (1996–99, 2000–03 [comparator], 2004–07, 2008–10). We estimated life expectancy by calendar period of initiation of ART. FINDINGS: 88 504 patients were included in our analyses, of whom 2106 died during the first year of ART and 2302 died during the second or third year of ART. Patients starting ART in 2008–10 had lower all-cause mortality in the first year after ART initiation than did patients starting ART in 2000–03 (adjusted HR 0·71, 95% CI 0·61–0·83). All-cause mortality in the second and third years after initiation of ART was also lower in patients who started ART in 2008–10 than in those who started in 2000–03 (0·57, 0·49–0·67); this decrease was not fully explained by viral load and CD4 cell count at 1 year. Rates of non-AIDS deaths were lower in patients who started ART in 2008–10 (vs 2000–03) in the first year (0·48, 0·34–0·67) and second and third years (0·29, 0·21–0·40) after initiation of ART. Between 1996 and 2010, life expectancy in 20-year-old patients starting ART increased by about 9 years in women and 10 years in men. INTERPRETATION: Even in the late ART era, survival during the first 3 years of ART continues to improve, which probably reflects transition to less toxic antiretroviral drugs, improved adherence, prophylactic measures, and management of comorbidity. Prognostic models and life expectancy estimates should be updated to account for these improvements

Cohort Profile: Antiretroviral Therapy Cohort Collaboration (ART-CC)

The advent of effective combination antiretroviral therapy (ART) in 1996 resulted in fewer patients experiencing clinical events, so that some prognostic analyses of individual cohort studies of human immunodeficiency virus-infected individuals had low statistical power. Because of this, the Antiretroviral Therapy Cohort Collaboration (ART-CC) of HIV cohort studies in Europe and North America was established in 2000, with the aim of studying the prognosis for clinical events in acquired immune deficiency syndrome (AIDS) and the mortality of adult patients treated for HIV-1 infection. In 2002, the ART-CC collected data on more than 12,000 patients in 13 cohorts who had begun combination ART between 1995 and 2001. Subsequent updates took place in 2004, 2006, 2008, and 2010. The ART-CC data base now includes data on more than 70 000 patients participating in 19 cohorts who began treatment before the end of 2009. Data are collected on patient demographics (e.g. sex, age, assumed transmission group, race/ethnicity, geographical origin), HIV biomarkers (e.g. CD4 cell count, plasma viral load of HIV-1), ART regimen, dates and types of AIDS events, and dates and causes of death. In recent years, additional data on co-infections such as hepatitis C; risk factors such as smoking, alcohol and drug use; non-HIV biomarkers such as haemoglobin and liver enzymes; and adherence to ART have been collected whenever available. The data remain the property of the contributing cohorts, whose representatives manage the ART-CC via the steering committee of the Collaboration. External collaboration is welcomed. Details of contacts are given on the ART-CC website (www.art-cohort-collaboration.org

A Frameshift Mutation in Golden Retriever Dogs with Progressive Retinal Atrophy Endorses SLC4A3 as a Candidate Gene for Human Retinal Degenerations

Progressive retinal atrophy (PRA) in dogs, the canine equivalent of retinitis pigmentosa (RP) in humans, is characterised by vision loss due to degeneration of the photoreceptor cells in the retina, eventually leading to complete blindness. It affects more than 100 dog breeds, and is caused by numerous mutations. RP affects 1 in 4000 people in the Western world and 70% of causal mutations remain unknown. Canine diseases are natural models for the study of human diseases and are becoming increasingly useful for the development of therapies in humans. One variant, prcd-PRA, only accounts for a small proportion of PRA cases in the Golden Retriever (GR) breed. Using genome-wide association with 27 cases and 19 controls we identified a novel PRA locus on CFA37 (praw = 1.94×10−10, pgenome = 1.0×10−5), where a 644 kb region was homozygous within cases. A frameshift mutation was identified in a solute carrier anion exchanger gene (SLC4A3) located within this region. This variant was present in 56% of PRA cases and 87% of obligate carriers, and displayed a recessive mode of inheritance with full penetrance within those lineages in which it segregated. Allele frequencies are approximately 4% in the UK, 6% in Sweden and 2% in France, but the variant has not been found in GRs from the US. A large proportion of cases (approximately 44%) remain unexplained, indicating that PRA in this breed is genetically heterogeneous and caused by at least three mutations. SLC4A3 is important for retinal function and has not previously been associated with spontaneously occurring retinal degenerations in any other species, including humans

Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies

BACKGROUND: The life expectancy of people with HIV taking antiretroviral therapy (ART) has increased substantially over the past 25 years. Most previous studies of life expectancy were based on data from the first few years after starting ART, when mortality is highest. However, many people with HIV have been successfully treated with ART for many years, and up-to-date prognosis data are needed. We aimed to estimate life expectancy in adults with HIV on ART for at least 1 year in Europe and North America from 2015 onwards. METHODS: We used data for people with HIV taking ART from the Antiretroviral Therapy Cohort Collaboration and the UK Collaborative HIV Cohort Study. Included participants started ART between 1996 and 2014 and had been on ART for at least 1 year by 2015, or started ART between 2015 and 2019 and survived for at least 1 year; all participants were aged at least 16 years at ART initiation. We used Poisson models to estimate the associations between mortality and demographic and clinical characteristics, including CD4 cell count at the start of follow-up. We also estimated the remaining years of life left for people with HIV aged 40 years who were taking ART, and stratified these estimates by variables associated with mortality. These estimates were compared with estimates for years of life remaining in a corresponding multi-country general population. FINDINGS: Among 206 891 people with HIV included, 5780 deaths were recorded since 2015. We estimated that women with HIV at age 40 years had 35·8 years (95% CI 35·2-36·4) of life left if they started ART before 2015, and 39·0 years (38·5-39·5) left if they started ART after 2015. For men with HIV, the corresponding estimates were 34·5 years (33·8-35·2) and 37·0 (36·5-37·6). Women with CD4 counts of fewer than 49 cells per μL at the start of follow-up had an estimated 19·4 years (18·2-20·5) of life left at age 40 years if they started ART before 2015 and 24·9 years (23·9-25·9) left if they started ART after 2015. The corresponding estimates for men were 18·2 years (17·1-19·4) and 23·7 years (22·7-24·8). Women with CD4 counts of at least 500 cells per μL at the start of follow-up had an estimated 40·2 years (39·7-40·6) of life left at age 40 years if they started ART before 2015 and 42·0 years (41·7-42·3) left if they started ART after 2015. The corresponding estimates for men were 38·0 years (37·5-38·5) and 39·2 years (38·7-39·7). INTERPRETATION: For people with HIV on ART and with high CD4 cell counts who survived to 2015 or started ART after 2015, life expectancy was only a few years lower than that in the general population, irrespective of when ART was started. However, for people with low CD4 counts at the start of follow-up, life-expectancy estimates were substantially lower, emphasising the continuing importance of early diagnosis and sustained treatment of HIV. FUNDING: US National Institute on Alcohol Abuse and Alcoholism and UK Medical Research Council